Cabozantinib and sunitinib are targeted drugs used to combat advanced renal cell carcinoma (aRCC).

Open-label phase II clinical trial including 157 adult patients with aRCC.

Randomized into treatment groups (cabozantinib or sunitinib).

Survival plots partitioned into three health states:
- **TWiST**—Time before disease progression without toxicity
- **TOX**—Time before disease progression with toxicity
- **REL**—Time after disease progression until death ('RELapse')

Evaluated drug impact using **Q-TWiST** (Quality-adjusted Time without Symptoms of disease or Toxicity of treatment).

**Q-TWiST combines both the length and quality of survival into a single value**

First-line treatment with cabozantinib provides longer quality-adjusted survival than sunitinib in patients with aRCC.

**Mean time spent before disease progression and without toxicity was significantly longer for cabozantinib**

**Q-TWiST is significantly longer for cabozantinib than sunitinib**